GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: BIIB122 | DNL-151 | DNL151
Compound class:
Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026). It was subsequently matched to example 78 in Denali Therapeutics' patent US9932325B2 [1] and [3]. The patent claims compounds as inhibitors of LRRK2 for the potential to treat neurodegenerative diseases such as Parkinson's disease. Review of Denali's declared pipeline indicates that liradasertib is likely the INN for their LRRK2 clinical lead DNL151 (formerlyBIIB122).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||